Esmya® (ulipristal acetate)
Uterine Fibroids
ApprovedMarketed in some ex-EU markets; not marketed in EU/UK
Key Facts
Indication
Uterine Fibroids
Phase
Approved
Status
Marketed in some ex-EU markets; not marketed in EU/UK
Company
About Organon
Organon is a publicly traded, diversified healthcare company that emerged as a spin-off from Merck & Co. (known as MSD outside the U.S. and Canada) in June 2021. The company's portfolio is built around three core pillars: a leading women's health franchise, a growing portfolio of biosimilars, and a stable of established brands across various therapeutic areas. With a global commercial footprint and a commitment to addressing unmet needs, particularly in women's health, Organon aims to drive sustainable growth through its existing portfolio, pipeline development, and strategic business development.
View full company profileOther Uterine Fibroids Drugs
| Drug | Company | Phase |
|---|---|---|
| Sonalleve® MR-HIFU | Profound Medical | Commercial |